Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT03487211

Comparative Efficacy of Duloxetine vs Escitalopram in Patients With Fibromyalgia (CORTEX)

Sponsor: Shaheed Zulfiqar Ali Bhutto Medical University

Updated 9 times since 2018 Last updated: Feb 25, 2020 Started: Apr 9, 2018 Primary completion: Feb 26, 2020 Completion: Feb 26, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03487211, this PHASE2/PHASE3 trial focuses on Fibromyalgia and remains completed. Sponsored by Shaheed Zulfiqar Ali Bhutto Medical University, it has been updated 9 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Mar 2020 — Jan 2021 [monthly]

Completed PHASE2_PHASE3

Status: Recruiting → Completed · Phase: PHASE3 → PHASE2_PHASE3
Oct 2019 — Mar 2020 [monthly]

Recruiting PHASE3

▶ Show 4 earlier versions

May 2019 — Oct 2019 [monthly]

Recruiting PHASE3
Oct 2018 — May 2019 [monthly]

Recruiting PHASE3
Jun 2018 — Oct 2018 [monthly]

Recruiting PHASE3
May 2018 — Jun 2018 [monthly]

Recruiting PHASE3

First recorded

Apr 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shaheed Zulfiqar Ali Bhutto Medical University

Data source: Shaheed Zulfiqar Ali Bhutto Medical University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Islamabad, Pakistan